Osteogenesis imperfecta: an update on clinical features and therapies

Eur J Endocrinol. 2020 Oct;183(4):R95-R106. doi: 10.1530/EJE-20-0299.

Abstract

Osteogenesis imperfecta (OI) is an inherited skeletal dysplasia characterized by bone fragility and skeletal deformities. While the majority of cases are associated with pathogenic variants in COL1A1 and COL1A2, the genes encoding type I collagen, up to 25% of cases are associated with other genes that function within the collagen biosynthesis pathway or are involved in osteoblast differentiation and bone mineralization. Clinically, OI is heterogeneous in features and variable in severity. In addition to the skeletal findings, it can affect multiple systems including dental and craniofacial abnormalities, muscle weakness, hearing loss, respiratory and cardiovascular complications. A multi-disciplinary approach to care is recommended to address not only the fractures, reduced mobility, growth and bone pain but also other extra-skeletal manifestations. While bisphosphonates remain the mainstay of treatment in OI, new strategies are being explored, such as sclerostin inhibitory antibodies and TGF beta inhibition, to address not only the low bone mineral density but also the inherent bone fragility. Studies in animal models have expanded the understanding of pathomechanisms of OI and, along with ongoing clinical trials, will allow to develop better therapeutic approaches for these patients.

Publication types

  • Review

MeSH terms

  • Animals
  • Endocrinology / methods
  • Endocrinology / trends*
  • Fractures, Bone / diagnosis
  • Fractures, Bone / epidemiology
  • Fractures, Bone / etiology
  • Fractures, Bone / therapy
  • Humans
  • Osteogenesis / physiology
  • Osteogenesis Imperfecta / diagnosis*
  • Osteogenesis Imperfecta / epidemiology
  • Osteogenesis Imperfecta / pathology
  • Osteogenesis Imperfecta / therapy*